OABI Financials: Revenue Breakdown, Margins & Competitor Comparison
The article provides a financial overview of OmniAb Inc (OABI), detailing its revenue streams, profitability margins, and a comparison with competitors. OABI generates revenue primarily from services, with significant contributions from license and milestone, and royalty revenues. The company exhibits negative gross, operating, and net margins, as well as a negative Return on Equity, indicating financial challenges when benchmarked against competitors like ALMU and BKKT.
Leerink reiterates Outperform on OmniAb stock after partner trial fails
Leerink Partners has reiterated an Outperform rating and a $10.00 price target on OmniAb, Inc. despite a Phase 3 trial failure by its partner Immunovant. The firm expects OmniAb to meet its $25 million to $30 million guidance and sees IMVT-1402 as a significant asset for the company, with potential future milestones and royalties. The article also notes recent positive analyst activity and OmniAb's Q4 financial results, where it surpassed EPS expectations despite a revenue decline.
Analysts Offer Insights on Healthcare Companies: Merck & Company (MRK) and OmniAb (OABI)
BMO Capital and Truist Financial analysts have issued bullish ratings for Merck & Company (MRK) and OmniAb (OABI), respectively. Evan Seigerman of BMO Capital maintained a Buy rating and set a $135.00 price target for MRK, while Srikripa Devarakonda of Truist Financial maintained a Buy rating for OABI. Both companies are in the Healthcare sector and have positive analyst consensus ratings.
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
OmniAb Inc. (OABI) is highlighted as one of the top penny stocks with potential for high returns despite missing Q4 revenue estimates. The company reported growing its partner base and program portfolio, attributing its business outlook to differentiated technologies and focusing on innovation, including the recent launch of OmniUltra(TM). The article suggests that while OABI has potential, other AI stocks might offer even greater returns.
Here Is Why You Should Not Ignore OmniAb Inc. (OABI)
OmniAb Inc. (OABI) reported Q4 revenue of $8.4 million, below consensus estimates, but ended 2025 with 107 active partners and 407 active programs. CEO Matt Foehr highlighted the company's differentiated technologies and the recent launch of OmniUltra™ as key drivers for growth and partner acquisition. OmniAb provides licenses for discovery research technology to pharmaceutical and biotech companies, focusing on creating and screening diverse antibody repertoires.
If You Invested $1,000 in OmniAb, Inc. (OABI)
This article analyzes the investment performance of OmniAb, Inc. (OABI) over various periods, showing significant negative returns for investors, especially compared to the S&P 500. It also provides an overview of OmniAb's business, focusing on its proprietary antibody and peptide discovery technology platforms, such as OmniRat, OmniMouse, OmniChicken, OmniUltra, and xPloration, and its licensing-based business model in the life sciences sector. The company primarily enables drug discovery for partners rather than direct therapeutic commercialization.
OmniAb files to sell 21.25M shares of common stock for holders
OmniAb has filed to sell 21.25 million shares of its common stock. This offering is on behalf of existing holders, indicating a secondary offering rather than a primary issuance by the company itself.
OmniAb files to sell 21.25M shares of common stock for holders
OmniAb has filed to sell 21.25 million shares of its common stock. These shares are being offered by existing holders of the stock. No further details about the offering or the holders were provided.
OmniAb (OABI) Q4 2025 Earnings Call Transcript
OmniAb (OABI) reported strong year-end results for 2025, expanding its partner base to 107 and active programs to 407, with significant advancements in its clinical pipeline. The company also launched new technologies, OmniUltra and Exploration, which are expected to drive future revenue growth and diversify its business. Despite a decrease in 2025 revenue, OmniAb provided optimistic 2026 guidance, forecasting increased revenue and controlled operating expenses, positioning itself for future cash flow positivity.
OmniAb 2025 Growth: 107 Partners, 407 Programs, and New OmniUltra Launch - News and Statistics
OmniAb reported positive business momentum for 2025, expanding to 107 partners and 407 programs, and strategically launching its new OmniUltra platform. This growth, alongside the development of its Exploration platform, positions the company for sustainable expansion, potential milestone revenue, and future royalty streams. The report also highlights a comprehensive analysis of the antisera industry in the United States, detailing demand, supply, trade flows, and forecasts to 2035.
OmniAb Earnings Call Highlights Platform Growth, Cash Path
OmniAb's recent Q4 earnings call revealed a dual outlook, emphasizing significant strategic momentum through partner and program growth and new technology platforms, alongside near-term financial challenges like declining 2025 revenue and continued net losses. Despite these pressures, the company is building a strong foundation with a multibillion-dollar milestone backlog and disciplined cost management, aiming for future royalty-driven revenue streams that support its 2026 operating plan and path toward cash-flow positivity.
OmniAb Earnings Call Highlights Platform Growth, Cash Path
OmniAb's Q4 earnings call revealed a mix of strong strategic momentum and near-term financial pressures. The company reported significant growth in partners and programs, a multibillion-dollar milestone backlog, and new technology platforms like OmniUltra and xPloration, all contributing to a foundation for future royalty revenue. Despite these advancements, OmniAb faced revenue declines in 2025 and is experiencing ongoing net losses, emphasizing the continued volatility of its milestone-driven financial model.
OmniAb (NASDAQ:OABI) Upgraded to Hold at Wall Street Zen
Wall Street Zen has upgraded OmniAb (NASDAQ: OABI) from "sell" to "hold," though the company still faces financial challenges, including missed earnings and revenue estimates in its latest quarter, deeply negative net margin, and negative return on equity. Despite the upgrade, company insiders have been selling shares, while institutional investors hold a significant portion of the stock. OmniAb, a biotechnology company specializing in therapeutic antibody discovery, operates with an average analyst rating of "Moderate Buy" and a consensus target price of $6.67.
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for the fourth quarter and full year 2025, detailing a decrease in revenue for both periods compared to 2024, primarily due to declines in license and service revenue, partially offset by an increase in milestone and royalty revenue and new xPloration revenue. Despite the revenue decrease, the company expanded its partner base to 107 and active programs to 407, including 32 in clinical development or commercialization. OmniAb also provided 2026 financial guidance, projecting revenue between $25 million and $30 million, and highlighted the recent launch of OmniUltra™ technology.
OmniAb Inc reports results for the quarter ended December 31 - Earnings Summary
OmniAb Inc. (OABI) has released its earnings summary for the quarter that ended on December 31. This report was distributed through Reuters, as indicated by Refinitiv.
Benchmark Maintains Buy on OmniAb, Inc. (OABI) March 2026
Benchmark has reaffirmed its Buy rating on OmniAb, Inc. (OABI) following the company's Q4 results, indicating continued analyst confidence despite a slight stock dip. Stifel also reiterated its Buy rating, citing partner growth and commercial momentum for the company, which has a market capitalization of $215,114,268 and trades near $1.81. Meyka AI assigns OABI a "B" grade based on various financial and market comparisons, suggesting a cautiously constructive view for investors.
Benchmark reiterates Buy on OmniAb stock, keeps $4 target
Benchmark has reiterated a Buy rating and a $4.00 price target on OmniAb, Inc. (NASDAQ:OABI) despite the company missing revenue and net loss estimates in its fourth-quarter fiscal 2025 results. The firm cited OmniAb's expanding development partners, new product launches like OmniUltra, and a strengthened balance sheet as key reasons. Separately, Stifel also maintained a Buy rating with a $9.00 price target, highlighting year-over-year growth in active partners and programs, attributing it to a favorable environment for pharmaceutical and biotech R&D.
OmniAb, Inc. (NASDAQ:OABI) Q4 2025 Earnings Call Transcript
OmniAb, Inc. reported its Q4 and full-year 2025 financial results, highlighting a strategic shift towards innovative technologies and operational efficiency. The company saw growth in active partners and programs, introduced new platforms like OmniUltra and xPloration, and provided revenue guidance for 2026. Management discussed their trajectory towards being cash flow positive, driven by a maturing portfolio and disciplined cost control.
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) reported a Q4 loss of $0.11 per share, missing the Zacks Consensus Estimate of a $0.08 loss and failing to beat revenue estimates with $8.38 million. The company's shares have underperformed the S&P 500 this year, and its current Zacks Rank is #3 (Hold), suggesting it will perform in line with the market. Investors are advised to monitor future earnings calls and estimate revisions, with the next quarter's EPS estimated at -$0.11 on $7.43 million in revenues.
OmniAb Reports Fourth Quarter and Full Year 2025 Financial Results and Business Highlights
OmniAb, Inc. reported its financial results for the fourth quarter and full year 2025, highlighting an expanded base of 107 active partners and 407 active programs, including 32 in clinical development or commercialization. The company launched OmniUltra™ which is designed to attract new partners by strengthening its ability to isolate picobodies™, and provided financial guidance for 2026 expecting revenue between $25 million to $30 million. Full-year revenue for 2025 was $18.7 million, down from $26.4 million in 2024, with a net loss of $64.8 million.
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) reported a Q4 loss of $0.11 per share, missing the Zacks Consensus Estimate of a $0.08 loss, and revenues of $8.38 million, falling short of estimates by 5.14%. The company has consistently missed revenue estimates over the past four quarters and its shares have declined by 6.5% year-to-date. The stock currently holds a Zacks Rank #3 (Hold), indicating it is expected to perform in line with the market.
OmniAb Inc (NASDAQ:OABI) Reports Q4 and Full-Year 2025 Earnings Miss, Provides 2026 Outlook
OmniAb Inc (NASDAQ:OABI) reported a miss on Q4 and full-year 2025 earnings and revenue, with the company's shares showing a muted after-hours reaction. The biotechnology platform company provided a 2026 revenue outlook of $25 million to $30 million, which is below analyst estimates, while emphasizing its expanding partner network and recent technology launches like OmniUltra™. The financial results reflect the inherent volatility of a platform biotechnology company, with future success tied to partner milestones and clinical trial progressions.
Earnings call transcript: OmniAb beats Q4 2025 EPS forecast, stock rises
OmniAb Inc. reported Q4 2025 EPS of -$0.11, exceeding the forecast of -$0.13, which caused its stock to rise by 4.62%. Despite a 22.2% decline in revenue to $8.4 million, the company demonstrated improved operational efficiency by reducing operating expenses by 9.7%. OmniAb projects 2026 revenue between $25 million and $30 million and expects to end the year with a cash balance of $30 million to $35 million, maintaining a focus on cost discipline and innovative platforms like OmniUltra and xPloration to drive future growth.
OmniAb, Inc. (OABI) Reports Q4 Loss, Misses Revenue Estimates
OmniAb, Inc. (OABI) reported a Q4 loss of $0.11 per share, missing the Zacks Consensus Estimate of a $0.08 loss and falling short of revenue estimates with $8.38 million. The company's shares have declined 6.5% since the beginning of the year. Investors are now looking to management's commentary and future earnings expectations, with the stock currently holding a Zacks Rank #3 (Hold).
OmniAb Reports $50.3 Million Revenue for 2025 with 15% Annual Growth and Expanded Partnerships
OmniAb announced its financial results for the full year 2025, reporting total revenues of $50.3 million, a 15% increase from 2024. The company also saw a 10% rise in Q4 revenue, reaching $14.2 million. OmniAb highlighted expanded collaborations, new agreements, and advancements in its antibody discovery platform, along with investments in R&D contributing to slightly increased operating expenses.
OmniAb (NASDAQ: OABI) outlines 2026 guidance after lower 2025 revenue
OmniAb, Inc. reported weaker financial results for 2025 with revenue of $18.7 million, down from $26.4 million in 2024, and a net loss of $64.8 million. Despite this, the company provided 2026 guidance forecasting revenue between $25 million and $30 million, and a year-end cash balance of $30 million to $35 million, alongside continued cost control measures. OmniAb highlights its expanded partner base, 407 active programs, and the recent launch of its OmniUltra transgenic chicken platform as key drivers for future growth and royalty revenue.
OmniAb Inc expected to post a loss of 9 cents a share - Earnings Preview
OmniAb Inc (OABI) is expected to report an earnings loss of 9 cents per share, according to this earnings preview. The article, a brief report from Refinitiv, provides no further details on the company's financial outlook or the context of the anticipated loss.
A Look Ahead: OmniAb's Earnings Forecast
OmniAb (NASDAQ: OABI) is expected to announce its quarterly earnings on March 4, 2026, with analysts forecasting an EPS of $-0.08. The company's past earnings have shown price drops following reports, and its stock is down 48.83% over the last 52 weeks. OmniAb, which specializes in therapeutic antibody discovery, faces challenges in revenue growth and net margin but shows strong Return on Equity and Return on Assets.
OmniAb to Participate at the Leerink Partners Global Healthcare Conference
OmniAb, Inc. (NASDAQ: OABI) announced its participation in the Leerink Global Healthcare Conference from March 8-11, 2026, in Miami. Management will present a corporate overview on March 10th and hold one-on-one meetings with registered investors. The company licenses its cutting-edge discovery research technology, powered by Biological Intelligence™, to pharmaceutical and biotech companies for developing next-generation therapeutics.
OmniAb (OABI) Projected to Post Earnings on Wednesday
OmniAb (NASDAQ:OABI) is scheduled to release its Q4 2025 earnings after market close on Wednesday, March 4th, with analysts forecasting an EPS of ($0.08) and revenue around $9.003 million. Recent insider activity shows sales by the CEO and CFO, reducing their positions. Despite a "Moderate Buy" consensus from analysts, the stock trades at $1.73, while institutions own 72.08% of the company.
OABIW Financials: Income Statement, Balance Sheet & Cash Flow
This article provides a comprehensive financial overview of OmniAb Inc (OABIW), detailing its income statement, balance sheet, and cash flow for both annual and quarterly periods. It highlights key financial metrics, including profitability, revenue growth, leverage, and liquidity, along with an assessment of the company's financial health, indicating weak profitability and strong liquidity but negative cash flow and low earnings quality. The report also addresses frequently asked questions regarding OmniAb Inc's financial performance and position.
OmniAb to Participate at the Leerink Partners Global Healthcare Conference
OmniAb, Inc. (NASDAQ: OABI) announced its participation at the Leerink Global Healthcare Conference, scheduled for March 8-11, 2026, in Miami. Management will present a corporate overview on March 10th and hold one-on-one meetings with registered investors. The company specializes in licensing advanced discovery research technology to enable the development of next-generation therapeutics using its proprietary OmniAb platform.
Form 4: FOEHR MATTHEW W reports multiple insider transactions in OABI
Matthew W. Foehr, President and CEO of OmniAb, Inc. (OABI), reported multiple insider transactions in a recent Form 4 filing. The filing indicates transactions totaling 93,670 shares at a weighted average price of $1.70 per share, which included the vesting of Restricted Stock Units and a subsequent "sell-to-cover" transaction for tax withholding obligations. Following these reported activities, Foehr's direct holdings in OmniAb, Inc. stand at 4,375,787 shares.
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (NASDAQ: OABI) will release its financial results for the quarter and year ending December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will also host a conference call and webcast on the same day at 4:30 p.m. Eastern time to discuss these results and provide business updates.
OmniAb to Report Fourth Quarter 2025 Financial Results on March 4
OmniAb, Inc. (NASDAQ: OABI) announced it will report its financial results for the fourth quarter and full year ended December 31, 2025, after the U.S. financial markets close on Wednesday, March 4, 2026. The company will host a conference call on the same day at 4:30 p.m. Eastern time to discuss the results and provide business updates. A live and replay webcast with slides will also be available for interested parties.
Matthew Foehr Sells 30,843 Shares of OmniAb (NASDAQ:OABI) Stock
OmniAb CEO Matthew Foehr sold 30,843 shares of OABI stock, valued at over $52,000, reducing his stake by 0.70%. The biotech company's stock trades around $1.71, with mixed analyst ratings and high institutional ownership. Other executives and a director also recently sold shares.
OmniAb (NASDAQ:OABI) Insider Charles Berkman Sells 9,673 Shares
OmniAb director Charles Berkman sold 9,673 shares for $16,540.83, reducing his stake by 2.4%. This sale is part of broader insider selling activity from the CEO and CFO, while institutional ownership remains high at 72.08%. The stock trades near $1.71, and analyst ratings are mixed, with a "Moderate Buy" consensus target of $6.67 contrasting with a Weiss "sell" rating.
Insider Selling: OmniAb (NASDAQ:OABI) CFO Sells 9,301 Shares of Stock
OmniAb (NASDAQ:OABI) CFO Kurt Gustafson sold 9,301 shares of the company's stock for $15,904.71 on February 18, 2026, reducing his stake by 3.34%. This sale is part of a broader pattern of insider selling by the CEO and a director around the same time, despite "Moderate Buy" analyst ratings and increased institutional ownership. The stock is currently trading around $1.71, below its 50-day and 200-day simple moving averages.
Insider Selling: OmniAb (NASDAQ:OABI) Insider Sells 6,990 Shares of Stock
OmniAb (NASDAQ:OABI) insider Charles Berkman sold 6,990 shares of the company's stock for approximately $11,883 on February 17, 2026, reducing his stake by 1.79%. Following the sale, Berkman now owns 383,623 shares valued at about $652,159. The stock traded up 0.6% to $1.71, with a market cap of $246.16 million, and institutional investors own 72.08% of the shares.
OmniAb (NASDAQ:OABI) CFO Sells $11,607.60 in Stock
OmniAb CFO Kurt Gustafson sold 6,828 shares of the company's stock for $11,607.60, reducing his stake by 2.56%. The biotechnology company's stock recently traded at $1.71, with institutional investors owning about 72% and analysts holding a consensus "Moderate Buy" rating.
OmniAb (OABI) chief legal officer Berkman sells $11883 in stock
Charles S. Berkman, Chief Legal Officer of OmniAb, Inc. (NASDAQ:OABI), sold 6,990 shares of common stock for approximately $11,883 on February 17, 2026. This sale occurred after the vesting of 13,542 restricted stock units (RSUs) on February 16, 2026. Following the transaction, Berkman directly owns 383,623 shares of OmniAb common stock.
OmniAb Updates Bylaws to Align with SEC Proxy Rules
OmniAb (OABI) has updated its bylaws to align with SEC universal proxy rules, effective January 30, 2026. These revisions tighten disclosure and procedural requirements for shareholder nominations and business proposals, aiming to enhance transparency and reinforce the company's control over the nomination process. Despite significant financial challenges, OmniAb shows some optimism through positive technical indicators and strategic initiatives.
OmniAb, Inc.'s (NASDAQ:OABI) recent 10% pullback adds to one-year year losses, institutional owners may take drastic measures
OmniAb, Inc. (NASDAQ:OABI) has experienced a 10% stock pullback recently, contributing to a 42% loss over the past year. Institutional investors, who hold a significant 36% ownership and endured the highest losses, may consider drastic measures if the decline continues. Hedge funds and private equity firms also hold substantial stakes, indicating multiple influential parties involved in the company's ownership structure.
OmniAb’s Earnings Call: Progress Amid Challenges
The article from MSN appears to be a placeholder or has missing content, as it only contains the title "OmniAb’s Earnings Call: Progress Amid Challenges" and the source "MSN" without any body text. Therefore, it is impossible to summarize any detailed information about OmniAb's earnings call or the progress and challenges mentioned in the title. The content provided is insufficient to extract any meaningful financial data, company performance, or analyst perspectives.
Analysts Offer Insights on Healthcare Companies: Novan (NOVN) and OmniAb (OABI)
Two analysts have issued bullish sentiments on healthcare companies Novan (NOVN) and OmniAb (OABI). While the article mentions Novan, it only provides details for OmniAb, where analyst Matt Hewitt from Craig-Hallum maintained a Buy rating, noting a consensus of Strong Buy with a $6.75 price target.
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb, Inc. (NASDAQ: OABI) has launched its new OmniUltra™ platform, the first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework, at the 2025 Antibody Engineering & Therapeutics Conference. This innovative platform broadens therapeutic opportunities beyond conventional antibodies and introduces picobodies™, the smallest known natural antibody-derived binding domain. OmniUltra is designed to deliver pre-optimized specificity, affinity, and structural stability for various applications, reinforcing OmniAb's leadership in drug discovery innovation.
Launch of OmniUltra Expands OmniAb’s Reach into New Markets and Applications, Advances Leadership in Antibody Discovery Technologies
OmniAb, Inc. has launched its new OmniUltra™ platform, the industry's first transgenic chicken engineered to express ultralong CDRH3 domains on a human antibody framework. This platform broadens therapeutic opportunities beyond conventional antibodies, enabling the discovery of novel binding modes and access to challenging targets, and facilitating applications in areas like bispecifics, multispecifics, CAR-T, and stand-alone peptide therapeutics. OmniUltra also allows for the isolation of picobodies™, the smallest natural antibody-derived binding domains, and represents a pioneering advancement in antibody and peptide discovery.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
OmniAb (NASDAQ: OABI) insiders who invested US$1.59 million in the last year have seen their holdings appreciate by US$277,000, thanks to a 10% stock gain. This included a significant US$1 million purchase by President Matthew Foehr at a price below the current market value, suggesting insiders see value in the company. Overall, insiders bought more shares than they sold, and their collective ownership stands at 12%, aligning their interests with other shareholders.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
Insiders at OmniAb, Inc. have seen a significant appreciation of US$277k on their US$1.59m investment over the last 12 months, largely due to a 10% stock gain. While individual transactions vary, there has been more insider buying than selling, indicating confidence in the company, despite it currently incurring losses. Insiders own 12% of the company, suggesting good alignment with shareholders.
OmniAb Insiders Enjoying US$277k Appreciation On US$1.59m Investment
Insiders at OmniAb, Inc. (NASDAQ:OABI) have seen a US$277k appreciation on their US$1.59m investment over the last year, coinciding with a 10% increase in the company's market value. While one significant purchase was made below the current price, overall insider buying exceeded selling, indicating confidence in the company's future despite current losses. Insiders collectively own 12% of OmniAb, aligning their interests with other shareholders.
